Axon Enterprise (NASDAQ:AXON) Director Sells $270,139.08 in Stock

Axon Enterprise, Inc (NASDAQ:AXON) Director Caitlin Elizabeth Kalinowski sold 564 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $478.97, for a total value of $270,139.08. Following the transaction, the director directly owned 3,632 shares in the company, valued at approximately $1,739,619.04. The trade was a 13.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $513.20 on Friday. The business’s fifty day simple moving average is $407.52 and its 200-day simple moving average is $491.96. The company has a market cap of $41.36 billion, a PE ratio of 206.10, a PEG ratio of 8.75 and a beta of 1.45. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. Axon Enterprise, Inc has a 12-month low of $339.01 and a 12-month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The business had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The business’s quarterly revenue was up 33.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.47 earnings per share. Analysts expect that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Axon Enterprise

Hedge funds have recently added to or reduced their stakes in the business. NEOS Investment Management LLC boosted its stake in shares of Axon Enterprise by 82.7% during the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock worth $18,206,000 after acquiring an additional 11,482 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Axon Enterprise by 1.3% during the 4th quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock worth $242,241,000 after acquiring an additional 5,419 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after acquiring an additional 376,904 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Axon Enterprise during the 4th quarter worth about $13,116,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Axon Enterprise by 93.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,365 shares of the biotechnology company’s stock worth $13,270,000 after acquiring an additional 11,262 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AXON. Craig Hallum reissued a “buy” rating and issued a $820.00 target price on shares of Axon Enterprise in a research report on Wednesday, February 25th. Piper Sandler cut their target price on Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. The Goldman Sachs Group set a $535.00 target price on Axon Enterprise in a research report on Thursday, May 7th. TD Cowen cut their target price on Axon Enterprise from $950.00 to $825.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Finally, Citizens Jmp cut their target price on Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $712.75.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.